▼ bearish
ImpactNot rated
PhaseNot stated
Time to marketNot stated
| Date | Drug | Event | 1 day |
|---|---|---|---|
| Dec 1, 2025 | ML-007C-MA | Fast Track | −5.4% |
| Trial | Status | Primary completion |
|---|---|---|
| A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia | Completed | Jun 4, 2026 |
| ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD) | Completed | Mar 10, 2026 |